A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Early Phase 1
Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Drug: lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Blue Earth Therapeutics Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06516510
- Locations
- 🇳🇱
Radboud UMC, Nijmegen, Gelderland, Netherlands
🇺🇸Biogenix Molecular, Miami, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1
Recruiting
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate CancermCRPCUrogenital NeoplasmsProstatic NeoplasmsProstatic Diseases
- Interventions
- Drug: 177Lu-rhPSMA-10.1 injectionDrug: Lutetium (177Lu) rhPSMA-10.1 InjectionDiagnostic Test: 18F-rhPSMA-7.3 injectionDiagnostic Test: 18F-rhPSMA-7.3 injection (in phase 1 only)
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Blue Earth Therapeutics Ltd
- Target Recruit Count
- 82
- Registration Number
- NCT05413850
- Locations
- 🇺🇸
Biogenix Molecular, Miami, Florida, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, United States
© Copyright 2025. All Rights Reserved by MedPath